05.07.2017 - 07:03:12

SHOP APOTHEKE EUROPE: Accelerated growth continues with revenue increase of +54% to more than EUR 126 million in 1st HY 2017.


SHOP APOTHEKE EUROPE: Accelerated growth continues with revenue increase of +54% to more than EUR 126 million in 1st HY 2017.

International sales more than tripled to EUR 34 million. Growth of 31% in Germany results in further expansion of market leadership. Guidance for FY 2017 reaffirmed.

Venlo/Cologne, 05 July 2017. In the first half of 2017, Europe's leading OTC-online pharmacy SHOP APOTHEKE EUROPE N.V. (OTC = over the counter) has continued to grow at the upper end of its guidance. According to preliminary calculations, the group increased revenues by +54% to more than EUR 126 million compared to EUR 82 million in first half 2016.

In its core segment "Germany", SHOP APOTHEKE EUROPE increased revenues by 31% to about EUR 92 million (1st HY 2016: EUR 70 million). The company thus grew twice as fast as the German OTC-mail-order market, which is expected to increase by almost 15% in full year 2017 according to the experts from Sempora Consulting. As a result, SHOP APOTHEKE EUROPE is further expanding its market leadership in the German OTC-online market.

Revenues in the European markets France, Italy, Spain, Austria, Belgium and the Netherlands, are recorded in the "International" segment. They more than tripled to EUR 34 million (1st HY 2016: EUR 11 million) during the reporting period. This makes SHOP APOTHEKE EUROPE the fastest-growing OTC-online pharmacy in Europe.

The segment "Germany Services", posted revenues of EUR 0.5 million after elimination of intragroup transactions (1st HY 2016: EUR 0.8 million).

In consideration of the company's dynamic growth in the first half of 2017, the Board of Management has reaffirmed its guidance for the 2017 fiscal year, projecting a 45% to 55% increase in consolidated revenues. The acceleration in growth is primarily driven by international business. Management also expects a positive impact from the overall positive market environment and from the continuously growing shift from offline- to online-shopping. Based on economies of scale, improvements in efficiency and further automation, management expects an improvement of the consolidated EBITDA margin in 2017 to around -2% to -3% (2016: -3.3%).

SHOP APOTHEKE EUROPE will publish its complete half-year report as scheduled on 26 July 2017.



SHOP APOTHEKE EUROPE is Continental Europe's leading online OTC pharmacy with a portfolio that focuses on OTC medication and pharmacy-related beauty and care products (BPC). The Company operates online pharmacies in Germany, Austria, France, Belgium, Italy, Spain and the Netherlands. In Germany, the TÜV-certified is the market leader in terms of traffic. SHOP APOTHEKE EUROPE delivers a broad range of more than 100,000 original products to more than 2.2 million active customers (as of July 2017) quickly and at attractive prices. In addition, SHOP APOTHEKE EUROPE provides comprehensive and consistent pharmaceutical services.

SHOP APOTHEKE EUROPE generated sales of more than EUR 126 million in the first half of 2017 and a growth of +54% compared to the same period last year. Headquartered in Venlo (the Netherlands), SHOP APOTHEKE EUROPE also has offices in Cologne, Düsseldorf, Paris and Tongeren, Belgium. The online pharmacy has been listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) since 13 October 2016.


26 July 2017 Publication of the Half-Year Report 2017 13 November 2017 Publication of the Third Quarter Results 2017  




29 - 31 August 2017 Commerzbank Sector Conference, Frankfurt 06 - 08 September 2017 Citi Global Technology Conference 2017, New York 18 - 20 September 2017 Berenberg & Goldman Sachs German Corporate Conference, München 04 - 07 Dezember 2017 Berenberg European Conference, London  



Trade and public media: Sven Schirmer Mobil: +49 152 28 50 63 61 E-Mail:

Financial media: Thomas Schnorrenberg Mobil: +49 151 46 53 13 17 E-Mail:

Investor Relations: Dr. Ulrich Wandel Telefphone: +31 77 850 6117 E-Mail:


This announcement does not constitute a public offer or an offer to subscribe to any securities in any jurisdiction. The offer was made exclusively on the basis of the company's securities prospectus that had been published in connection with the offer. The shares have already been sold. This announcement contains forward-looking statements that relate to the future course of business and future financial performance, as well as future transactions or developments concerning SHOP APOTHEKE EUROPE. The bases of these statements are current expectations and assumptions of SHOP APOTHEKE EUROPE's management, of which a large number are outside SHOPE APOTHEKE EUROPE's sphere of influence. These statements are therefore subject to a variety of risks and uncertainties. If such risks and uncertainties occur, or if the underlying expectations do not materialize or the assumptions made are not correct, the actual events, both positive and negative, may differ materially from those events contained in the forward-looking statements. SHOP APOTHEKE EUROPE assumes no obligation to update these forward-looking statements or to correct them in the event of occurrences or developments other than those anticipated. Such updates or corrections are not intended.

05.07.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at

Language: English

Company: SHOP APOTHEKE EUROPE N.V. Dirk Hartogweg 14 5928 LV Venlo

Netherlands Phone: 0800 - 200 800 300 Fax: 0800 - 90 70 90 20 E-mail: Internet: ISIN: NL0012044747 WKN: A2AR94 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange   End of News DGAP News Service

589339  05.07.2017 


Amazon wird sich schwarzärgern, aber …

… wir schenken Ihnen den Report „Börsenpsychologie - Markttechnik für Trader“ heute trotzdem kostenfrei. Normalerweise kostet der Report im Onlinehandel 39,99 Euro.

Sie können sich den genialen Report heute jedoch absolut kostenfrei sichern. Wir senden Ihnen den Report vollkommen KOSTENFREI zu.

Jetzt HIER klicken und dank richtigen Timing reich an der Börse werden!